OK so you thought the title of the other thread was out of date BUT unfortunately there is no way to edit thread titles.

So here is a new title

This one has got the charts at the top again & has a link to the old one.
http://www.moneyam.com/InvestorsRoom/posts.php?tid=5021

Looks like we've reached buying level again.

I got some more this morning at less than 20p

Apple- I've also been adding to my holding this week. Looks like the winter sales have gone on into Feb this year.

Not worried about the dips in the sp this week as I can see the situation
being reversed by the end of this week and the sp heading northwards next week
as more investors pile into the stock ahead of the results.

I'm hoping to the sp at 35p by Mid-March 2005. However, time will tell.

1704 - I hope you are right as I intend to hold until mid-year, earliest.

Cobra CBF gave up dna after a relatively short period and moved into proteins and viruses.They seem to be the new babe on the block(plus MMG,of course).Unless there is another approach I think that OXB will drift a bit from now on.Held for six frustrating months,watching the day traders making lolly,because I bought at 20p.Finally made a nice bit because I sold at 27p . It was totally stressful. But then is'nt this whole business of the stk mkt a real worry at times.You are right to give yourself half a year,Pachandl.with your attitude,I would have been much happier last year...I wanted a quick buck.

Ethel - how ever long you hold the stock market is still worrying. At least the price seems to be consolidating so hopefully my patience will be eventually rewarded.

Pachandl-I think your strategy is a sensible one to hold at least until the
mid year. Personally I think that there will be opportunities to dip in and out
of this stock and make profits because of its volatility.

I've been following the market on Bloomberg TV today and was happy to
see that Merck and another large US Pharma (cannot recall the name) are
thinking of making a few acquisitions in the British pharma sector including
Bio-Techs. Apparently they have both got millions to invest. It would not
surprise me to see OXB being mentioned in the financial press as likely target
or takeover talks being announced within the next few weeks.

Pleased to see the sp stopping its falls today. I remain confident that there
will be a bounce back and my target price of 35p being achieved by mid
March 05. It will take more of a 'tree shake' by the MMs to get me out of this stock before the real fun begins.

Ethel-Pleased to hear that you eventually sold out at a profit after 6 months.
It can be stressful holding stocks like OXB but personally that is half the
attraction for me. Knowing that with luck and the right timing you can make
quick and sizeable profits in the stock market. Its feels great when it comes
right but very stressful if it does not go to plan. As well as carrying out my
own researchI I often rely on 'gut feeling' when I invest and remain confident
that OXB will deliver.

All the Best!

I presume this is the news that caused the jump in the share price just now, don't know why it hasn't come through as an RNS:

Oxford BioMedica said today that its collaborative partner Viragen Inc. reported that an antibody designed to treat malignant melanoma (anti-GD3 antibody) has been successfully detected in the blood of a founder transgenic rooster after the antibody was introduced using Oxford BioMedica's proprietary LentiVector(R) gene delivery system.
Viragen, in collaboration with the Roslin Institute, is developing avian transgenic biomanufacturing for the purpose of using chickens as bioreactors for the efficient and economical production of human pharmaceutical protein-based drugs in their eggs.
The latest achievement is the first in a series of steps designed to confirm that a humanised antibody can be produced in subsequent generations of chickens and demonstrate a fully intact structure capable of its intended therapeutic function.
-0-

ICV Edited News from Dow Jones
1357 GMT Feb 17 2005

RD- Thanks for the above information.

I was was flinking between the Bloomberg TV Channel and Kiss TV this afternoon when I saw the sp down by half a pence and then up by the same amount within a few minutes. I turned to my eldest son and said if that's what watching LL Cool Jay videos does to share prices I want more of it. Thank god for MTV Base and Kiss TV Channels this week they've certainly kept my blood pressure down with this stock.

The statement released today is positive news and bodes well for the other
results we are all eagerly awaiting (well I am anyway). I'm feeling more
bullish about this stock everyday 'ya get me'!

Financial Times 17/02/05 (Article: FTSE up on media strength'by Tony Tassell,
Philip Stafford and Chris Flood)

'More than 5.7 million shares were traded in Oxford Biomedica, the pharmaceutical group which ended takeover talks with an unnamed party earlier
this month. Rumours said it could shortly announce a deal to licence out further development of Trovax, its cancer vaccine. The shares were unchanged at
20p'.

I'm feeling more bullish about this stock everyday 'ya get me'!

1704 - FT - Beat me to posting it by 21mins - saw it earlier this afternoon but forgot to cut & paste.

is there any news about another merger with a big company?????????? has anyone one got news??????

Probable reason for the increase in sp:

BOSTON (AFX) -- Biotechnology and pharmaceutical issues scored modest gains Wednesday after a series of brokerage upgrades and gains in the broader market.

The Amex Biotechnology Index edged up 0.5 percent to 509.12 and the Amex Pharmaceutical Index added 0.2 percent to 314.79.

Human Genome Sciences advanced 1.3 percent to $11.15 after the genomics firm said it had completed enrollment for a Phase II clinical trial for its drug candidate HGS-ETR1, a treatment for advanced colorectal cancer.

Onyx Pharmaceuticals was the biggest winner among biotech issues, shooting up more than 9 percent at one point before resting at $30.08, up 7.4 percent. Analysts at Morgan Stanley upped their rating of the stock to 'overweight.'

Progenics Pharmaceuticals was upgraded by CIBC to 'outperform,' and the stock rose 4.6 percent to $22.04.

ImClone Systems shares inched up 1.8 percent to $42.57 after analysts at Morgan Stanley initiated coverage of the stock with an 'overweight' rating.

Gilead Sciences gained 1.9 percent to $33.77 in early afternoon on news that its HIV treatment Truvada had been approved by European regulators.

This story was supplied by MarketWatch. For further information see www.marketwatch.com.

Is still moving north - any reason known out there or is it speculation that agin a merger or aquisition is back in play

Thanks for the above info guys.

We are on the up again, looks like I was right last week when I thought that it had reached buying level again, I just about caught the bottom again when I bought some more with the profits from the last big rise.

Two interesting articles in the 'Guardian' and 'The Independent' newspapers
today concerning OXB. Nice to see the colour blue again on the PC Screen.

Anyone notice that Vernalis sp was up this morning as well. Co-incidence
or what?

1704

what was written in the articles???

Guardian Newspaper (Article Title 'WPP rises above FTSE
doldrums'by Neil Hume dated 24/02/05)

'In the smaller companies world, biotech group Oxford Biomedica
gained 1p to 20p on hopes that trial results for its
cancer vaccine Trovax in colorectal cancer will impress and
pave the way for a licensing deal with a large drug company.
OXB recently terminated takeover talks with a mystery bidder'.


The Independent Newspaper (Market Report by Stephen Foley,
dated 24/02/05)

'Amid the small-caps, there were rumours of contract wins
for Retail Decisions, the computer data security firm. And
OXB, where merger talks collapsed this month, ticked a
penny higher to 20p on hopes for receipt of another bid'.

I feel more bullish about OXB everyday 'ya get me'.

1704 - not Vernalis. See below for reason that it rose today:

Vernalis attracted support, rising 3p to 77p after the company revealed plans to raise 30.3m via a fully underwritten placing and open offer of 43.2m new ordinary shares at 70p each.

The UK biotech group will use the proceeds to strengthen its financial position prior to receipt of a milestone payment of $40m from Endo Pharmaceuticals, on the expected approval of frovatriptan for menstrually related migraine in the first half of 2007.

Vernalis also announced that it intends to establish a US commercial infrastructure through the exercise of its option with Endo Pharmaceuticals to co-promote frovatriptan in the US. Vernalis licensed exclusive North American sales and marketing rights to frovatriptan (marketed as Frova in the US) to Endo last July.

1704: i thank you

Accord-No problem! I should have provided the information
when I made the post.

Pachandl-Thanks for your info which does provide clear
reasons why the sp of Vernalis rose yesterday.

Anyone a subscriber to the FT website? If so could they
verify or not whether this was written in the FT Small
Caps section yesterday.

'Vernalis, maker of migraine drug Frovatriptan, raised
30.3m after placing 43m shares at 70p each. It could
use the cash for acquisitions'....

Pachandl (OXB/ADVFN Post 3706 last night). I hope
someone can verify this because if they can it would
support my theory that Vernalis are very much in the
picture and now intend to bid for OXB and not seek a
merger as they previously did.